A Palmitoylation-Associated lncRNA Signature as a Prognostic Biomarker and Its Correlation With the Immune Microenvironment in Lung Adenocarcinoma
Open Access
- 22 May 2026
- journal article
- Published by IMR Press in Frontiers in Bioscience-Landmark
- Vol. 31 (5) , 48267
Abstract
Background: Lung adenocarcinoma (LUAD) is recognized as the predominant subtype of non-small cell lung cancer (NSCLC), characterized by its aggressive behavior and notable capacity for metastasis. Recent studies have uncovered the significance of palmitoylation, a vital post-translational modification, in regulating biological functions such as cellular signaling and protein localization, suggesting its potential role in cancer biology. However, the implications of palmitoylation-associated long non-coding RNAs (lncRNAs) in LUAD pathology remain insufficiently characterized. Methods: Utilizing publicly available datasets, we conducted an extensive bioinformatics analysis to evaluate the expression and prognostic significance of palmitoylation-associated lncRNAs in LUAD. Our analysis identified 13 lncRNAs as potential prognostic biomarkers. Specifically, we sought to develop a prognostic model based on these lncRNAs to improve our understanding of their contribution to LUAD prognosis. The robustness of the prognostic model was subsequently verified through survival analysis and receiver operating characteristic (ROC) curve assessments. Results: This study established a prognostic risk model based on 13 palmitoylation-related lncRNAs, demonstrating excellent predictive performance, with area under the curve (AUC) values of 0.743, 0.724, and 0.748 for 1-year, 3-year, and 5-year overall survival, respectively. Multivariate Cox regression analysis indicated that the model’s risk score serves as an independent prognostic predictor, surpassing traditional clinicopathological features. Differential expression analysis and quantitative reverse transcription polymerase chain reaction (qRT-PCR) validation revealed significant downregulation of AL157895.1 in LUAD tissues and cell lines, whereas AL355472.3, SALRNA1, AL590666.4, AC026355.2, and LINC00862 were significantly upregulated. Importantly, low expression of AL157895.1 was strongly associated with poor patient prognosis. Conclusions: The findings underscore the potential of palmitoylation-associated lncRNAs as independent prognostic markers for patients with LUAD, paving the way for more personalized treatment approaches. Future studies should further explore their biological mechanisms.Keywords
Funding Information
- Scientific Research Fund Project of the Hunan Provincial Health Commission (20253699)
- Hunan Provincial Graduate Research and Innovation General Project (LXBZZ2024254)
This publication has 70 references indexed in Scilit:
- Identification of palmitoylation-related lncRNAs as prognostic biomarkers and immune modulators in HCCDiscover Oncology, 2025
- LncRNA LINC01128 promotes prostate cancer cell proliferation, metastasis, and epithelial-mesenchymal transition by modulating miR-27b-3pJournal of Cancer Research and Clinical Oncology, 2025
- Identification and validation of palmitoylation metabolism-related signature for liver hepatocellular carcinomaBiochemical and Biophysical Research Communications, 2023
- Loss of LncRNA DUXAP8 synergistically enhanced sorafenib induced ferroptosis in hepatocellular carcinoma via SLC7A11 de‐palmitoylationClinical and Translational Medicine, 2023
- Involvement of ZDHHC9 in lung adenocarcinoma: regulation of PD-L1 stability via palmitoylationIn Vitro Cellular & Developmental Biology - Animal, 2023
- Construction of a Pearson- and MIC-Based Co-expression Network to Identify Potential Cancer GenesInterdisciplinary Sciences: Computational Life Sciences, 2021
- Management of Ground-Glass Opacities in the Lung Cancer SpectrumThe Annals of Thoracic Surgery, 2020
- Lung Cancer in the YoungLung, 2019
- LncRNA CRNDE promotes hepatocellular carcinoma progression by upregulating SIX1 through modulating miR‐337‐3pJournal of Cellular Biochemistry, 2019
- Mast cells in tumor growth: Angiogenesis, tissue remodelling and immune-modulationBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2009